Christian Kersten

Summary

Country: Norway

Publications

  1. pmc Cetuximab alleviates neuropathic pain despite tumour progression
    Christian Kersten
    Center for Cancer Treatment, Southern Norway Hospital Trust, Kristiansand, Norway
    BMJ Case Rep 2012:. 2012
  2. doi request reprint Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain
    C Kersten
    Center for Cancer Treatment, Sørlandet Hospital, Pb 416, Kristiansand 4604, Norway
    Br J Anaesth 115:761-7. 2015
  3. pmc FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Postboks 4953 Nydalen, 0424 Oslo, Norway
    BMC Cancer 14:340. 2014
  4. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
  5. pmc Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: a pilot study
    Marte G Cameron
    Center for Cancer Treatment, Sørlandet Hospital Trust, Service Box 416, 4604 Kristiansand, Norway
    BMC Res Notes 4:252. 2011
  6. ncbi request reprint BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
    Christian Kersten
    Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
    Exp Hematol 34:72-81. 2006
  7. pmc BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
    Christian Kersten
    Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
    BMC Immunol 6:9. 2005
  8. ncbi request reprint Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
    Marte G Cameron
    a Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway
    Acta Oncol 55:1400-1407. 2016
  9. ncbi request reprint Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
    Einar A Sivertsen
    Department of Immunology, Institute of Cancer Research, Rikshospitalet Radiumhospitalet Medical Centre, Oslo, Norway
    Eur J Immunol 37:2937-48. 2007
  10. doi request reprint Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
    Marte Grønlie Cameron
    Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway Electronic address
    Radiother Oncol 115:314-20. 2015

Collaborators

Detail Information

Publications19

  1. pmc Cetuximab alleviates neuropathic pain despite tumour progression
    Christian Kersten
    Center for Cancer Treatment, Southern Norway Hospital Trust, Kristiansand, Norway
    BMJ Case Rep 2012:. 2012
    ..Mitogen-activated protein kinase (MAPK)-signalling is believed to be an important driver of neuropathic pain and therefore, the authors hypothesise a direct inhibition of MAPK-signalling by cetuximab in neuronal or glial cells...
  2. doi request reprint Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain
    C Kersten
    Center for Cancer Treatment, Sørlandet Hospital, Pb 416, Kristiansand 4604, Norway
    Br J Anaesth 115:761-7. 2015
    ..The aim of this report was to explore if EGFR-I attenuated neuropathic pain in humans...
  3. pmc FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Postboks 4953 Nydalen, 0424 Oslo, Norway
    BMC Cancer 14:340. 2014
    ....
  4. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
    ....
  5. pmc Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: a pilot study
    Marte G Cameron
    Center for Cancer Treatment, Sørlandet Hospital Trust, Service Box 416, 4604 Kristiansand, Norway
    BMC Res Notes 4:252. 2011
    ..A secondary aim was to explore patients' willingness to answer existential questions in the setting of palliative pelvic radiation...
  6. ncbi request reprint BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
    Christian Kersten
    Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
    Exp Hematol 34:72-81. 2006
    ..Bone morphogenetic proteins (BMPs) are multifunctional cytokines previously found to regulate hematopoietic stem cells. In the present study, we have explored the role of BMP-6 in human B progenitor cells...
  7. pmc BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
    Christian Kersten
    Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
    BMC Immunol 6:9. 2005
    ..A potential role of BMP-6 in the immune system has been implied by various studies of malignant and rheumatoid diseases. In the present study, we explored the role of BMP-6 in normal human peripheral blood B cells...
  8. ncbi request reprint Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
    Marte G Cameron
    a Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway
    Acta Oncol 55:1400-1407. 2016
    ..Aims were to evaluate symptom severity, quality of life (QOL) and toxicity after PPRT...
  9. ncbi request reprint Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
    Einar A Sivertsen
    Department of Immunology, Institute of Cancer Research, Rikshospitalet Radiumhospitalet Medical Centre, Oslo, Norway
    Eur J Immunol 37:2937-48. 2007
    ..However, we did not observe significant changes in Id protein expression in CD4(+) T cells. Altogether, the data indicate a role for BMP-6 in human T lineage cells...
  10. doi request reprint Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
    Marte Grønlie Cameron
    Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway Electronic address
    Radiother Oncol 115:314-20. 2015
    ..Study aims were to evaluate changes in patient-reported target symptoms (TS), health-related quality of life (HRQOL) and toxicity following palliative pelvic radiotherapy (PPRT) of CRPC...
  11. doi request reprint Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
    Marte Grønlie Cameron
    Center for Cancer Treatment, Sørlandet Hospital Trust, Kristiansand, Norway Electronic address
    Radiother Oncol 110:55-60. 2014
    ..We aimed to provide an overview of the literature and to evaluate palliative pelvic radiotherapy of PC focusing on symptomatic effect, quality of life (QOL), and toxicity, and to determine the optimal radiotherapy schedule...
  12. doi request reprint The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker
    Anne Helene Køstner
    Department of Oncology, Southern Hospital Trust, Kristiansand, Norway
    J Surg Oncol 114:895-899. 2016
    ....
  13. pmc Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
    Marit Synnestvedt
    Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
    BMC Cancer 12:616. 2012
    ..The present study explores the use of DTCs to identify adjuvant insufficiently treated patients to be offered secondary adjuvant treatment intervention, and as a surrogate marker for therapy response...
  14. ncbi request reprint Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
    Christian Kersten
    Department of Immunology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
    Cancer Immunol Immunother 53:1119-26. 2004
    ..We conclude that the SEREX approach with a B-cell cDNA source is applicable in NHL. Furthermore, we identified genes with possible involvement in the pathogenesis of BL using this technique...
  15. pmc Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
    Marte Grønlie Cameron
    Center for Cancer Treatment, Sørlandet Hospital Trust, Kristiansand, Norway
    Acta Oncol 53:164-73. 2014
    ..Our aim was to review the efficacy and toxicity of palliative pelvic radiotherapy of symptomatic rectal cancer and to evaluate different fractionation schedules, based on published literature...
  16. doi request reprint Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer
    Christian Kersten
    Department of Oncology, Southern Hospital Trust, Kristiansand, Norway
    Acta Oncol 52:1691-8. 2013
    ..To characterize the stage-specific prognostic relevance of preoperative systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) patients...
  17. ncbi request reprint Spiritual Well-being in Patients With Metastatic Colorectal Cancer Receiving Noncurative Chemotherapy: A Qualitative Study
    Gudrun Rohde
    Author Affiliations Faculty of Health and Sport Sciences, University of Agder Dr Rohde Department of Clinical Research Dr Rohde, Center for Cancer Treatment Dr Kersten, and Department of Obstetrics and Gynecology Dr Vistad, Sorlandet Hospital HF and Department of Religion, Philosophy, and History, University of Agder Dr Mesel, Kristiansand, Norway
    Cancer Nurs . 2016
    ..Therefore, it is important for healthcare professionals to recognize the concept of SWB from the patient's point of view. A deeper understanding of how patients experience and reflect upon these issues might influence patient care...
  18. doi request reprint Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
    Maria Thomsen
    Department of Oncology, Oslo University Hospital, Oslo, Norway
    Oncotarget . 2016
    ....
  19. doi request reprint Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
    Paal Fr Brunsvig
    Department of Clinical Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
    Clin Cancer Res 17:6847-57. 2011
    ....